Cited by 21Lipoproteins and Cardiovascular HealthLipid metabolism and disordersGenetic Associations and Epidemiology

Prevalence of the Apolipoprotein E Arg145Cys Dyslipidemia At-Risk Polymorphism in African-Derived Populations

Open access
Abou Ziki, Maen D., Strulovici-Barel, Yael, Hackett, Neil R., Rodriguez-Flores, Juan L., Mezey, Jason G., Salit, Jacqueline, Radisch, Sharon, Hollmann, Charleen +6 more·2014·The American Journal of Cardiology

Abstract

Apolipoprotein E, a protein component of blood lipid particles, plays an important role in lipid transport. Different mutations in the apolipoprotein E gene have been associated with various clinical phenotypes. In an initiated study of Qataris, we observed that 17% of the African-derived genetic subgroup were heterozygotes for a rare Arg145Cys (R145C) variant that functions as a dominant trait with incomplete penetrance associated with type III hyperlipoproteinemia. On the basis of this observation, we hypothesized that the R145C polymorphism might be common in African-derived populations. The prevalence of the R145C variant was assessed worldwide in the "1000 Genomes Project" and in 1,012 whites and 1,226 African-Americans in New York, New York. The 1000 Genomes Project data demonstrated that the R145C polymorphism is rare in non-African-derived populations but present in 5% to 12% of Sub-Saharan African-derived populations. The R145C polymorphism was also rare in New York whites (1 of 1,012, 0.1%); however, strikingly, 53 of the 1,226 New York African-Americans (4.3%) were R145C heterozygotes. The lipid profiles of the Qatari and New York R145C heterozygotes were compared with those of controls. The Qatari R145C subjects had higher triglyceride levels than the Qatari controls (p <0.007) and the New York African-American R145C subjects had an average of 52% greater fasting triglyceride levels than the New York African-American controls (p <0.002). From these observations, likely millions of people worldwide derived from Sub-Saharan Africans are apolipoprotein E R145C. In conclusion, although larger epidemiologic studies are necessary to determine the long-term consequences of this polymorphism, the available evidence suggests it is a common cause of a mild triglyceride dyslipidemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2013.09.021

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [1]Davignon J Gregg RE Sing CF Apolipoprotein E polymorphism and atherosclerosis Arteriosclerosis 1988 8 1 21 3277611
  2. [2]Eichner JE Dunn ST Perveen G Thompson DM Stewart KE Stroehla BC Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol 2002 155 487 495 11882522
  3. [3]Mahley RW Rall SC Jr Scriver CR Beaudet AL Sly WS Valle D Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism The Metabolic and Molecular Bases of Inherited Disease 7 New York McGraw-Hill 1995 1953 1980
  4. [4]Mahley RW Rall SC Jr Apolipoprotein E: far more than a lipid transport protein Annu Rev Genomics Hum Genet 2000 1 507 537 11701639
  5. [5]Hunter-Zinck H Musharoff S Salit J Al-Ali KA Chouchane L Gohar A Matthews R Butler MW Fuller J Hackett NR Crystal RG Clark AG Population genetic structure of the people of Qatar Am J Hum Genet 2010 87 17 25 20579625 PMC2896773
  6. [6]Bener A Zirie M Janahi IM Al-Hamaq AO Musallam M Wareham NJ Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar Diabetes Res Clin Pract 2009 84 99 106 19261345
  7. [7]de Villiers WJ van der Westhuyzen DR Coetzee GA Henderson HE Marais AD The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance Arterioscler Thromb Vasc Biol 1997 17 865 872 9157949
  8. [8]Ji ZS Fazio S Mahley RW Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia J Biol Chem 1994 269 13421 13428 8175773
  9. [9]Gerdes LU Gerdes C Hansen PS Klausen IC Faergeman O Dyerberg J The apolipoprotein E polymorphism in Greenland Inuit in its global perspective Hum Genet 1996 98 546 550 8882873
  10. [10]Feussner G Scharnagl H Scherbaum C Acar J Dobmeyer J Lohrmann J Wieland H Marz W Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts J Lipid Res 1996 37 1632 1645 8864947
  11. [11]Shore VG Shore B Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components Biochemistry 1973 12 502 507 4345806
  12. [12]Mahley RW Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer’s disease Isr J Med Sci 1996 32 414 429 8682647
  13. [13]Cullen P Cignarella A Brennhausen B Mohr S Assmann G von EA Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages J Clin Invest 1998 101 1670 1677 9541497 PMC508748
  14. [14]Smith JD Miyata M Ginsberg M Grigaux C Shmookler E Plump AS Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors J Biol Chem 1996 271 30647 30655 8940040
  15. [15]Riddell DR Graham A Owen JS Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease J Biol Chem 1997 272 89 95 8995232
  16. [16]Mistry MJ Clay MA Kelly ME Steiner MA Harmony JA Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary Cell Immunol 1995 160 14 23 7842480
  17. [17]Vogel T Guo NH Guy R Drezlich N Krutzsch HC Blake DA Panet A Roberts DD Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation J Cell Biochem 1994 54 299 308 8200910
  18. [19]Weisgraber KH Innerarity TL Mahley RW Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site J Biol Chem 1982 257 2518 2521 6277903
  19. [20]Rall SC Jr Mahley RW The role of apolipoprotein E genetic variants in lipoprotein disorders J Intern Med 1992 231 653 659 1619388
  20. [22]Raven P Johnson G Mason KA Losos JB Singer SS Genes within populations Biology 9 New York McGraw Hill 2010 401 402
  21. [23]Rizzo M Berneis K Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005 12 237 239 16205019
  22. [24]Morganroth J Levy RI Fredrickson DS The biochemical, clinical, and genetic features of type III hyperlipoproteinemia Ann Intern Med 1975 82 158 174 163608
  23. [25]Grunfeld C Kotler DP Hamadeh R Tierney A Wang J Pierson RN Hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 1989 86 27 31 2910092
  24. [26]Periard D Telenti A Sudre P Cheseaux JJ Halfon P Reymond MJ Marcovina SM Glauser MP Nicod P Darioli R Mooser V Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study Circulation 1999 100 700 705 10449690
  25. [29]Lohse P Rader DJ Brewer HB Jr Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia J Biol Chem 1992 267 13642 13646 1352296
  26. [30]Lohse P Mann WA Stein EA Brewer HB Jr Apolipoprotein E-4Philadelphia (Glu13----Lys, Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia J Biol Chem 1991 266 10479 10484 1674745

Cited by

Sorted by citations

Authors
Abou Ziki, M. D., Strulovici-Barel, Y., Hackett, N. R., Rodriguez-Flores, J. L., Mezey, J. G., Salit, J., Radisch, S., Hollmann, C., Chouchane, L., Malek, J., Zirie, M. A., Jayyuosi, A., Gotto, A. M., & Crystal, R. G.
Affiliations
  • Weill Cornell Medicine (US)
  • Cornell University (US)
  • Weill Cornell Medical College in Qatar (QA)
  • Hamad Medical Corporation (QA)
Corresponding author
Crystal, Ronald G.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2014-01
Volume
113
Issue
2
Pages
302-308
ISSN
0002-9149 (ISSN-L)
OpenAlex
W1971360302
Cited by
21
References
6
Citations by year
2025: 3 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 3
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • The American Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR000457)
  • National Heart, Lung, and Blood Institute (T32HL094284)
  • National Center for Research Resources (UL1RR024996)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
apolipoprotein E, type III hyperlipoproteinemia, prevalence, African Americans, sub-Saharan Africans, triglyceride levels, genetic variants, 1000 Genomes Project
MeSH terms
Alleles, Apolipoproteins E, Black or African American, DNA, Genotype, Humans, New York, Polymorphism, Genetic, Risk Factors, Prevalence, Polymerase Chain Reaction, Genetic Predisposition to Disease, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review